| abstract |
Disclosed are a class of amide compounds having novel structures or stereoisomers thereof or stereoisomer mixtures thereof and pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for the treatment of diseases, disorders, or conditions that benefit from the inhibition of PD1 or PD-L1 activity. The compounds of the present invention exhibit strong PD-1/PD-L1 blocking activity, and can reverse the T cell function inhibited by PD-L1. In addition, the compounds of the present invention can activate the NFAT signal pathway caused by the binding of PD-1/PD-L1, and can be absorbed orally, and have good pharmacokinetic properties. Therefore, the compounds of the present invention can be applied, alone or in combination with other drugs, in the treatment of diseases, disorders, or conditions that benefit from the inhibition of PD1 or PD-L1 activity, comprising infectious diseases, immune diseases, inflammatory diseases, and cancer. |